This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Gutierrez M , Moreno V , Heinhuis KM , Olszanski AJ , Spreafico A , Ong M , Chu Q , Carvajal RD , Trigo J , De Olza MO , Provencio M , De Vos FY , de Braud F , Leong S , Lathers D , Wang R , Ravindran P , Feng Y , Aanur P , Melero I
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Clin Cancer Res. 2021 Jan 15;27(2) :460-472
PMID: 33148673 URL: https://www.ncbi.nlm.nih.gov/pubmed/33148673
AbstractPURPOSE: This phase 1/2a study (NCT02737475) evaluated the safety and activity of BMS-986178, a fully human OX40 agonist immunoglobulin G1 monoclonal antibody, ± nivolumab and/or ipilimumab in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Patients (with non-small cell lung, renal cell, bladder, other advanced cancers) received BMS-986178 (20-320 mg) ± nivolumab (240-480 mg) and/or ipilimumab (1-3 mg/kg). The primary endpoint was safety. Additional endpoints included immunogenicity, pharmacodynamics, pharmacokinetics, and antitumor activity per RECIST version 1.1. RESULTS: Twenty patients received BMS-986178 monotherapy, and 145 received combination therapy in various regimens (including 2 patients receiving nivolumab monotherapy). With a follow-up of 1.1 to 103.6 weeks, the most common (≥ 5%) treatment-related adverse events (TRAEs) included fatigue, pruritus, rash, pyrexia, diarrhea, and infusion-related reactions. Overall, grade 3-4 TRAEs occurred in 1 of 20 patients (5%) receiving BMS-986178 monotherapy, 6 of 79 (8%) receiving BMS-986178 plus nivolumab, 0 of 2 receiving nivolumab monotherapy, 6 of 41 (15%) receiving BMS-986178 plus ipilimumab, and 3 of 23 (13%) receiving BMS-986178 plus nivolumab plus ipilimumab. No deaths occurred. No dose-limiting toxicities were observed with monotherapy, and the maximum tolerated dose was not reached in either the monotherapy or the combination escalation cohorts. No objective responses were seen with BMS-986178 alone; objective response rates ranged from 0% to 13% across combination therapy cohorts. CONCLUSION: In this study, BMS-986178 ± nivolumab and/or ipilimumab appeared to have a manageable safety profile, but no clear efficacy signal was observed above that expected for nivolumab and/or ipilimumab.
NotesGutierrez, Martin Orcid: 0000-0002-3642-2315 Moreno, Victor Orcid: 0000-0001-6099-4236 Heinhuis, Kimberley M Olszanski, Anthony J Orcid: 0000-0001-5276-5898 Spreafico, Anna Ong, Michael Orcid: 0000-0002-0347-5541 Chu, Quincy S Carvajal, Richard D Trigo, José Orcid: 0000-0002-4489-2683 Ochoa de Olza, Maria Orcid: 0000-0002-2445-6892 Provencio, Mariano De Vos, Filip de Braud, Filippo Leong, Stephen Orcid: 0000-0002-8838-8542 Lathers, Deanne Wang, Rui Ravindran, Palani Feng, Yan Aanur, Praveen Melero, Ignacio Journal Article United States Clin Cancer Res. 2021 Jan 15;27(2):460-472. doi: 10.1158/1078-0432.CCR-20-1830. Epub 2020 Nov 4.